VKORC1 mutations in patients with partial resistance to phenprocoumon

British Journal of Haematology

Volumn 148, Issue 6, 2010, Pages 955-957

  Schmeits, Peter C J ^a,b   Hermans, Mirjam H A ^a   Van Geest Daalderop, Johanna H H ^c   Poodt, Jeroen ^a   De Sauvage Nolting, Pernette R W ^d   Conemans, Jean M H ^a,b  

^a Molecular Diagnostics   (Russian Federation)

^b Laboratory for Pharmacology and Toxicology   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d Dutch Centre for Immigrants   (Netherlands)

Author keywords

Phenprocoumon; Resistance; Vitamin K epoxide reductase; VKORC1; Warfarin

Indexed keywords

ACENOCOUMAROL; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; OXIDOREDUCTASE; PHENPROCOUMON; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN S; PROTHROMBIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; ANTICOAGULANT AGENT; MIXED FUNCTION OXIDASE; VKORC1 PROTEIN, HUMAN;

5' UNTRANSLATED REGION; CARBOXYLATION; DRUG BLOOD LEVEL; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; AMINO ACID SEQUENCE; CASE REPORT; DRUG RESISTANCE; GENETICS; MOLECULAR GENETICS; MUTATION; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANTICOAGULANTS; DRUG RESISTANCE; HUMANS; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; MUTATION; PHENPROCOUMON; SEQUENCE ALIGNMENT; VITAMIN K EPOXIDE REDUCTASES;

EID: 77649210941     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.08017.x     Document Type: Letter

References (9)

1. Bodin, L., Horellou, M.H., Flaujac, C., Loriot, M.A. Samama, M.M. (2005) A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. Journal of Thrombosis and Haemostasis, 3, 1533 1535.
2. Harrington, D.J., Gorska, R., Wheeler, R., Davidson, S., Murden, S., Morse, C., Shearer, M.J. Mumford, A.D. (2008) Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. Journal of Thrombosis and Haemostasis, 6, 1663 1670.
3. Peoc'h, K., Pruvot, S., Gourmel, C., dit Sollier, C.B. Drouet, L. (2009) A new VKORC1 mutation leading to an isolated resistance to fluindione. British Journal of Haematology, 145, 841 843.
4. Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S., McLeod, H.L., Blough, D.K., Thummel, K.E., Veenstra, D.L. Rettie, A.E. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine, 352, 2285 2293.
5. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hortnagel, K., Pelz, H.J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E.G., Muller, C.R., Strom, T.M. Oldenburg, J. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 427, 537 541.
6. Schalekamp, T., Brasse, B.P., Roijers, J.F., Chahid, Y., Geest-Daalderop, J.H., Vries-Goldschmeding, H., van Wijk, E.M., Egberts, A.C. de Boer, A. (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clinical Pharmacology and Therapeutics, 80, 13 22.
7. Schalekamp, T., Brasse, B.P., Roijers, J.F., van Meegen, E., van der Meer, F.J., van Wijk, E.M., Egberts, A.C. de Boer, A. (2007) VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clinical Pharmacology and Therapeutics, 81, 185 193.
8. Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., Wood, P., Kesteven, P., Daly, A.K. Kamali, F. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106, 2329 2333.
9. Wilms, E.B., Touw, D.J., Conemans, J.M., Veldkamp, R. Hermans, M. (2008) A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. Journal of Thrombosis and Haemostasis, 6, 1224 1226.